1 4934 113 PATERNAL CHRONIC FOLATE SUPPLEMENTATION INDUCED THE TRANSGENERATIONAL INHERITANCE OF ACQUIRED DEVELOPMENTAL AND METABOLIC CHANGES IN CHICKENS. INCREASING EVIDENCE INDICATES THAT PATERNAL DIET CAN RESULT IN METABOLIC CHANGES IN OFFSPRING, BUT THE DEFINITE MECHANISM REMAINS UNCLEAR IN BIRDS. HERE, WE FED BREEDER COCKS FIVE DIFFERENT DIETS CONTAINING 0, 0.25, 1.25, 2.50 AND 5.00 MG KG(-1) FOLATE THROUGHOUT LIFE. PATERNAL FOLATE SUPPLEMENTATION (FS) WAS BENEFICIAL TO THE GROWTH AND ORGAN DEVELOPMENT OF BROILER OFFSPRING. MOST IMPORTANTLY, THE LIPID AND GLUCOSE METABOLISM OF BREEDER COCKS AND BROILER OFFSPRING WERE AFFECTED BY PATERNAL FS, ACCORDING TO BIOCHEMICAL AND METABOLOMIC ANALYSES. WE FURTHER EMPLOYED GLOBAL ANALYSES OF HEPATIC AND SPERMATOZOAL MESSENGER RNA (MRNA), LONG NON-CODING RNA (LNCRNA) AND MICRO RNA (MIRNA). SOME KEY GENES INVOLVED IN THE GLYCOLYSIS OR GLUCONEOGENESIS PATHWAY AND THE PPAR SIGNALLING PATHWAY, INCLUDING PEPCK, ANGPTL4 AND THRSP, WERE REGULATED BY DIFFERENTIALLY EXPRESSED HEPATIC AND SPERMATOZOAL MIRNAS AND LNCRNAS IN BREEDER COCKS AND BROILER OFFSPRING. MOREOVER, THE EXPRESSION OF ANGPTL4 COULD ALSO BE REGULATED BY DIFFERENTIALLY EXPRESSED MIRNAS AND LNCRNAS IN SPERMATOZOA VIA COMPETITIVE ENDOGENOUS RNA (CERNA) MECHANISMS. OVERALL, THIS MODEL SUGGESTS THAT PATERNAL FOLATE COULD TRANSGENERATIONALLY REGULATE LIPID AND GLUCOSE METABOLISM IN BROILER OFFSPRING AND THE EPIGENETIC TRANSMISSION MAY INVOLVE ALTERED SPERMATOZOAL MIRNAS AND LNCRNAS. 2019 2 3935 33 LIVER-SPECIFIC KNOCKDOWN OF CLASS IIA HDACS HAS LIMITED EFFICACY ON GLUCOSE METABOLISM BUT ENTAILS SEVERE ORGAN SIDE EFFECTS IN MICE. HISTONE DEACETYLASES (HDACS) ARE IMPORTANT REGULATORS OF EPIGENETIC GENE MODIFICATION THAT ARE INVOLVED IN THE TRANSCRIPTIONAL CONTROL OF METABOLISM. IN PARTICULAR CLASS IIA HDACS HAVE BEEN SHOWN TO AFFECT HEPATIC GLUCONEOGENESIS AND PREVIOUS APPROACHES REVEALED THAT THEIR INHIBITION REDUCES BLOOD GLUCOSE IN TYPE 2 DIABETIC MICE. IN THE PRESENT STUDY, WE AIMED TO EVALUATE THE POTENTIAL OF CLASS IIA HDAC INHIBITION AS A THERAPEUTIC OPPORTUNITY FOR THE TREATMENT +OF METABOLIC DISEASES. FOR THAT, SIRNAS SELECTIVELY TARGETING HDAC4, 5 AND 7 WERE SELECTED AND USED TO ACHIEVE A COMBINATORIAL KNOCKDOWN OF THESE THREE CLASS IIA HDAC ISOFORMS. SUBSEQUENTLY, THE HEPATOCELLULAR EFFECTS AS WELL AS THE IMPACT ON GLUCOSE AND LIPID METABOLISM WERE ANALYZED IN VITRO AND IN VIVO. THE TRIPLE KNOCKDOWN RESULTED IN A STATISTICALLY SIGNIFICANT DECREASE OF GLUCONEOGENIC GENE EXPRESSION IN MURINE AND HUMAN HEPATOCYTE CELL MODELS. A SIMILAR HDAC-INDUCED DOWNREGULATION OF HEPATIC GLUCONEOGENESIS GENES COULD BE ACHIEVED IN MICE USING A LIVER-SPECIFIC LIPID NANOPARTICLE SIRNA FORMULATION. HOWEVER, THE EFFICACY ON WHOLE BODY GLUCOSE METABOLISM ASSESSED BY PYRUVATE-TOLERANCE TESTS WERE ONLY LIMITED AND DID NOT OUTWEIGH THE SAFETY FINDINGS OBSERVED BY HISTOPATHOLOGICAL ANALYSIS IN SPLEEN AND KIDNEY. MECHANISTICALLY, AFFYMETRIX GENE EXPRESSION STUDIES PROVIDE EVIDENCE THAT CLASS IIA HDACS DIRECTLY TARGET OTHER KEY FACTORS BEYOND THE DESCRIBED FORKHEAD BOX (FOXP) TRANSCRIPTION REGULATORS, SUCH AS HEPATOCYTE NUCLEAR FACTOR 4 ALPHA (HNF4A). DOWNSTREAM OF THESE FACTORS SEVERAL ADDITIONAL PATHWAYS WERE REGULATED NOT MERELY INCLUDING GLUCOSE AND LIPID METABOLISM AND TRANSPORT. IN CONCLUSION, THE LIVER-DIRECTED COMBINATORIAL KNOCKDOWN OF HDAC4, 5 AND 7 BY THERAPEUTIC SIRNAS AFFECTED MULTIPLE PATHWAYS IN VITRO, LEADING IN VIVO TO THE DOWNREGULATION OF GENES INVOLVED IN GLUCONEOGENESIS. HOWEVER, THE EFFECTS ON GENE EXPRESSION LEVEL WERE NOT PARALLELED BY A SIGNIFICANT REDUCTION OF GLUCONEOGENESIS IN MICE. COMBINED KNOCKDOWN OF HDAC ISOFORMS WAS ASSOCIATED WITH SEVERE ADVERSE EFFECTS IN VIVO, CHALLENGING THIS APPROACH AS A TREATMENT OPTION FOR CHRONIC METABOLIC DISORDERS LIKE TYPE 2 DIABETES. 2020 3 4946 27 PATERNAL PSYCHOLOGICAL STRESS REPROGRAMS HEPATIC GLUCONEOGENESIS IN OFFSPRING. BOTH EPIDEMIOLOGIC AND EXPERIMENTAL ANIMAL STUDIES DEMONSTRATE THAT CHRONIC PSYCHOLOGICAL STRESS EXERTS ADVERSE EFFECTS ON THE INITIATION AND/OR PROGRESSION OF MANY DISEASES. HOWEVER, INTERGENERATIONAL EFFECTS OF THIS ENVIRONMENTAL INFORMATION REMAINS POORLY UNDERSTOOD. HERE, USING A C57BL/6 MOUSE MODEL OF RESTRAINT STRESS, WE SHOW THAT OFFSPRING OF STRESSED FATHERS EXHIBIT HYPERGLYCEMIA DUE TO ENHANCED HEPATIC GLUCONEOGENESIS AND ELEVATED EXPRESSION OF PEPCK. MECHANISTICALLY, WE IDENTIFY AN EPIGENETIC ALTERATION AT THE PROMOTER REGION OF THE SFMBT2 GENE, A MATERNALLY IMPRINTED POLYCOMB GENE, LEADING TO A DOWNREGULATION OF INTRONIC MICRORNA-466B-3P, WHICH POST-TRANSCRIPTIONALLY INHIBITS PEPCK EXPRESSION. IMPORTANTLY, HYPERGLYCEMIA IN F1 MICE IS REVERSED BY RU486 TREATMENT IN FATHERS, AND DEXAMETHASONE ADMINISTRATION IN F0 MICE PHENOCOPIES THE ROLES OF RESTRAINT STRESS. THUS, WE PROVIDE EVIDENCE SHOWING THE EFFECTS OF PATERNAL PSYCHOLOGICAL STRESS ON THE REGULATION OF GLUCOSE METABOLISM IN OFFSPRING, WHICH MAY HAVE PROFOUND IMPLICATIONS FOR OUR UNDERSTANDING OF HEALTH AND DISEASE RISK INHERITED FROM FATHERS. 2016 4 2316 25 EPIGENETIC REGULATION OF FRUCTOSE-1,6-BISPHOSPHATASE 1 BY HOST TRANSCRIPTION FACTOR SPECKLED 110 KDA DURING HEPATITIS B VIRUS INFECTION. HEPATITIS B VIRUS (HBV) IS THE LEADING CAUSE OF LIVER DISEASE RANGING FROM ACUTE AND CHRONIC HEPATITIS TO LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA (HCC). STUDIES HAVE REVEALED THAT HBV INFECTION BROADLY REPROGRAMMES THE HOST CELLULAR METABOLIC PROCESSES FOR VIRAL PATHOGENESIS. PREVIOUS REPORTS HAVE SHOWN THAT GLYCOLYSIS AND GLUCONEOGENESIS ARE AMONG THE MOST DEREGULATED PATHWAYS DURING HBV INFECTION. WE NOTED THAT DESPITE BEING ONE OF THE RATE-LIMITING ENZYMES OF GLUCONEOGENESIS, THE ROLE AND REGULATION OF FRUCTOSE-1,6-BISPHOSPHATASE 1 (FBP1) DURING HBV INFECTION IS NOT MUCH EXPLORED. IN THIS STUDY, WE REPORT FBP1 UPREGULATION UPON HBV INFECTION AND UNRAVEL A NOVEL MECHANISM OF EPIGENETIC REPROGRAMMING OF FBP1 BY HBV VIA UTILIZING HOST FACTOR SPECKLED 110 KDA (SP110). HERE, WE IDENTIFIED ACETYLATED LYSINE 18 OF HISTONE H3 (H3K18AC) AS A SELECTIVE INTERACTOR OF SP110 BROMODOMAIN. FURTHERMORE, WE FOUND THAT SP110 GETS RECRUITED ON H3K18AC-ENRICHED FBP1 PROMOTER, AND FACILITATES RECRUITMENT OF DEACETYLASE SIRTUIN 2 (SIRT2) ON THAT SITE IN THE PRESENCE OF HBV. SIRT2 IN TURN BRINGS ITS INTERACTOR AND TRANSCRIPTIONAL ACTIVATOR HEPATOCYTE NUCLEAR FACTOR 4-ALPHA TO THE PROMOTER, WHICH ULTIMATELY LEADS TO A LOSS OF DNA METHYLATION NEAR THE COGNATE SITE. INTERESTINGLY, THIS SP110 DRIVEN FBP1 REGULATION DURING INFECTION WAS FOUND TO PROMOTE VIRAL-BORNE HCC PROGRESSION. MOREOVER, SP110 CAN BE USED AS A PROGNOSTIC MARKER FOR THE HEPATITIS-MEDIATED HCC PATIENTS, WHERE HIGH SP110 EXPRESSION SIGNIFICANTLY LOWERED THEIR SURVIVAL. THUS, THE EPIGENETIC READER PROTEIN SP110 HAS POTENTIAL TO BE A THERAPEUTIC TARGET TO CHALLENGE HBV-INDUCED HCCS. 2022 5 2155 26 EPIGENETIC MECHANISMS AND METABOLIC REPROGRAMMING IN FIBROGENESIS: DUAL TARGETING OF G9A AND DNMT1 FOR THE INHIBITION OF LIVER FIBROSIS. OBJECTIVE: HEPATIC STELLATE CELLS (HSC) TRANSDIFFERENTIATION INTO MYOFIBROBLASTS IS CENTRAL TO FIBROGENESIS. EPIGENETIC MECHANISMS, INCLUDING HISTONE AND DNA METHYLATION, PLAY A KEY ROLE IN THIS PROCESS. CONCERTED ACTION BETWEEN HISTONE AND DNA-MEHYLTRANSFERASES LIKE G9A AND DNMT1 IS A COMMON THEME IN GENE EXPRESSION REGULATION. WE AIMED TO STUDY THE EFFICACY OF CM272, A FIRST-IN-CLASS DUAL AND REVERSIBLE G9A/DNMT1 INHIBITOR, IN HALTING FIBROGENESIS. DESIGN: G9A AND DNMT1 WERE ANALYSED IN CIRRHOTIC HUMAN LIVERS, MOUSE MODELS OF LIVER FIBROSIS AND CULTURED MOUSE HSC. G9A AND DNMT1 EXPRESSION WAS KNOCKED DOWN OR INHIBITED WITH CM272 IN HUMAN HSC (HHSC), AND TRANSCRIPTOMIC RESPONSES TO TRANSFORMING GROWTH FACTOR-BETA1 (TGFBETA1) WERE EXAMINED. GLYCOLYTIC METABOLISM AND MITOCHONDRIAL FUNCTION WERE ANALYSED WITH SEAHORSE-XF TECHNOLOGY. GENE EXPRESSION REGULATION WAS ANALYSED BY CHROMATIN IMMUNOPRECIPITATION AND METHYLATION-SPECIFIC PCR. ANTIFIBROGENIC ACTIVITY AND SAFETY OF CM272 WERE STUDIED IN MOUSE CHRONIC CCL(4) ADMINISTRATION AND BILE DUCT LIGATION (BDL), AND IN HUMAN PRECISION-CUT LIVER SLICES (PCLSS) IN A NEW BIOREACTOR TECHNOLOGY. RESULTS: G9A AND DNMT1 WERE DETECTED IN STROMAL CELLS IN AREAS OF ACTIVE FIBROSIS IN HUMAN AND MOUSE LIVERS. G9A AND DNMT1 EXPRESSION WAS INDUCED DURING MOUSE HSC ACTIVATION, AND TGFBETA1 TRIGGERED THEIR CHROMATIN RECRUITMENT IN HHSC. G9A/DNMT1 KNOCKDOWN AND CM272 INHIBITED TGFBETA1 FIBROGENIC RESPONSES IN HHSC. TGFBETA1-MEDIATED PROFIBROGENIC METABOLIC REPROGRAMMING WAS ABROGATED BY CM272, WHICH RESTORED GLUCONEOGENIC GENE EXPRESSION AND MITOCHONDRIAL FUNCTION THROUGH ON-TARGET EPIGENETIC EFFECTS. CM272 INHIBITED FIBROGENESIS IN MICE AND PCLSS WITHOUT TOXICITY. CONCLUSIONS: DUAL G9A/DNMT1 INHIBITION BY COMPOUNDS LIKE CM272 MAY BE A NOVEL THERAPEUTIC STRATEGY FOR TREATING LIVER FIBROSIS. 2021 6 3944 27 LNCRNA H19-EZH2 INTERACTION PROMOTES LIVER FIBROSIS VIA REPROGRAMMING H3K27ME3 PROFILES. LIVER FIBROSIS IS A WOUND-HEALING PROCESS CHARACTERIZED BY EXCESS FORMATION OF EXTRACELLULAR MATRIX (ECM) FROM ACTIVATED HEPATIC STELLATE CELLS (HSCS). PREVIOUS STUDIES SHOW THAT BOTH EZH2, AN EPIGENETIC REGULATOR THAT CATALYZES LYSINE 27 TRIMETHYLATION ON HISTONE 3 (H3K27ME3), AND LONG NON-CODING RNA H19 ARE HIGHLY CORRELATED WITH FIBROGENESIS. IN THE CURRENT STUDY, WE INVESTIGATED THE UNDERLYING MECHANISMS. VARIOUS MODELS OF LIVER FIBROSIS INCLUDING MDR2(-/-), BILE DUCT LIGATION (BDL) AND CCL(4) MICE WERE ADAPTED. WE FOUND THAT EZH2 WAS MARKEDLY UPREGULATED AND CORRELATED WITH H19 AND FIBROTIC MARKERS EXPRESSION IN THESE MODELS. ADMINISTRATION OF EZH2 INHIBITOR 3-DZNEP CAUSED SIGNIFICANT PROTECTIVE EFFECTS IN THESE MODELS. FURTHERMORE, TREATMENT WITH 3-DZNEP OR GSK126 SIGNIFICANTLY INHIBITED PRIMARY HSC ACTIVATION AND PROLIFERATION IN TGF-BETA-TREATED HSCS AND H19-OVEREXPREESING LX2 CELLS IN VIVO. USING RNA-PULL DOWN ASSAY COMBINED WITH RNA IMMUNOPRECIPITATION, WE DEMONSTRATED THAT H19 COULD DIRECTLY BIND TO EZH2. INTEGRATED ANALYSIS OF RNA-SEQUENCING (RNA-SEQ) AND CHROMATIN IMMUNOPRECIPITATION SEQUENCING (CHIP-SEQ) FURTHER REVEALED THAT H19 REGULATED THE REPROGRAMMING OF EZH2-MEDIATED H3K27ME3 PROFILES, WHICH EPIGENETICALLY PROMOTED SEVERAL PATHWAYS FAVORING HSCS ACTIVATION AND PROLIFERATION, INCLUDING EPITHELIAL-MESENCHYMAL TRANSITION AND WNT/BETA-CATENIN SIGNALING. IN CONCLUSION, HIGHLY EXPRESSED H19 IN CHRONIC LIVER DISEASES PROMOTES FIBROGENESIS BY REPROGRAMMING EZH2-MEDIATED EPIGENETIC REGULATION OF HSCS ACTIVATION. TARGETING THE H19-EZH2 INTERACTION MAY SERVE AS A NOVEL THERAPEUTIC APPROACH FOR LIVER FIBROSIS. 2023 7 2899 26 GC-MS-BASED URINARY ORGANIC ACID PROFILING REVEALS MULTIPLE DYSREGULATED METABOLIC PATHWAYS FOLLOWING EXPERIMENTAL ACUTE ALCOHOL CONSUMPTION. METABOLOMICS STUDIES OF DISEASES ASSOCIATED WITH CHRONIC ALCOHOL CONSUMPTION PROVIDE COMPELLING EVIDENCE OF SEVERAL PERTURBED METABOLIC PATHWAYS. MOREOVER, THE HOLISTIC APPROACH OF SUCH STUDIES GIVES INSIGHTS INTO THE PATHOPHYSIOLOGICAL RISK FACTORS ASSOCIATED WITH CHRONIC ALCOHOL-INDUCED DISABILITY, MORBIDITY AND MORTALITY. HERE, WE REPORT ON A GC-MS-BASED ORGANIC ACID PROFILING STUDY ON ACUTE ALCOHOL CONSUMPTION. OUR INVESTIGATION - INVOLVING 12 HEALTHY, MODERATE-DRINKING YOUNG MEN - SIMULATED A SINGLE BINGE DRINKING EVENT, AND INDICATED ITS METABOLIC CONSEQUENCES. WE GENERATED TIME-DEPENDENT DATA THAT PREDICTED THE METABOLIC PATHOPHYSIOLOGY OF THE ALCOHOL INTERVENTION. MULTIVARIATE STATISTICAL MODELLING WAS APPLIED TO THE LONGITUDINAL DATA OF 120 BIOLOGICALLY RELEVANT ORGANIC ACIDS, OF WHICH 13 PROVIDED STATISTICAL EVIDENCE OF THE ALCOHOL EFFECT. THE KNOWN ALCOHOL-INDUCED INCREASED NADH:NAD(+) RATIO IN THE CYTOSOL OF HEPATOCYTES CONTRIBUTED TO THE GLOBAL DYSREGULATION OF SEVERAL METABOLIC REACTIONS OF GLYCOLYSIS, KETOGENESIS, THE KREBS CYCLE AND GLUCONEOGENESIS. THE SIGNIFICANT PRESENCE OF 2-HYDROXYISOBUTYRIC ACID SUPPORTS THE EMERGING PARADIGM THAT THIS COMPOUND IS AN IMPORTANT ENDOGENOUS METABOLITE. ITS METABOLIC ORIGIN REMAINS ELUSIVE, BUT RECENT EVIDENCE INDICATED 2-HYDROXYISOBUTYRYLATION AS A NOVEL REGULATORY MODIFIER OF HISTONES. METABOLOMICS HAS THUS OPENED AN AVENUE FOR FURTHER RESEARCH ON THE REPROGRAMMING OF METABOLIC PATHWAYS AND EPIGENETIC NETWORKS IN RELATION TO THE SEVERE EFFECTS OF ALCOHOL CONSUMPTION. 2018 8 699 21 BROMODOMAIN PROTEIN 4 IS A KEY MOLECULAR DRIVER OF TGFBETA1-INDUCED HEPATIC STELLATE CELL ACTIVATION. LIVER FIBROSIS IS CHARACTERIZED BY THE EXCESSIVE DEPOSITION OF EXTRACELLULAR MATRIX IN LIVER. CHRONIC LIVER INJURY INDUCES THE ACTIVATION OF HEPATIC STELLATE CELL (HSCS), A KEY STEP IN LIVER FIBROGENESIS. THE ACTIVATED HSC IS THE PRIMARY SOURCE OF ECM AND CONTRIBUTES SIGNIFICANTLY TO LIVER FIBROSIS. TGFBETA1 IS THE MOST POTENT PRO-FIBROTIC CYTOKINE. BROMODOMAIN PROTEIN 4 (BRD4), AN EPIGENETIC READER OF HISTONE ACETYLATION MARKS, WAS CRUCIAL FOR PROFIBROTIC GENE EXPRESSION IN HSCS. THE PRESENT STUDY AIMED TO INVESTIGATE THE ROLES OF BRD4 IN TGFBETA1-DEPENDENT HSC ACTIVATION AND LIVER FIBROSIS, FOCUSING ON TGFBETA1-INDUCED ALTERATIONS OF THE LEVELS OF THE FIBROTIC-RELATED IMPORTANT PROTEINS IN HSCS BY EMPLOYING THE HETEROZYGOUS TGFBETA1 KNOCKOUT MICE AND BRD4 KNOCKDOWN IN VIVO AND IN VITRO. RESULTS REVEALED THAT BRD4 PROTEIN LEVEL WAS SIGNIFICANTLY UPREGULATED BY TGFBETA1 AND BRD4 KNOCKDOWN REDUCED TGFBETA1-INDUCED HSC ACTIVATION AND LIVER FIBROSIS. BRD4 WAS REQUIRED FOR THE INFLUENCES OF TGFBETA1 ON PDGFBETA RECEPTOR AND ON THE PATHWAYS OF SMAD3, STAT3, AND AKT. BRD4 ALSO MEDIATED TGFBETA1-INDUCED INCREASES IN HISTONE ACETYLTRANSFERASE P300, THE PIVOTAL PRO-INFLAMMATORY NFKB P65, AND TISSUE INHIBITOR OF METALLOPROTEINASE 1 WHEREAS BRD4 REDUCED CASPASE-3 PROTEIN LEVELS IN HSCS DURING LIVER INJURY, INDEPENDENT OF TGFBETA1. FURTHER EXPERIMENTS INDICATED THE INTERACTION BETWEEN TGFBETA1-INDUCED BRD4 AND NFKB P65 IN HSCS AND IN LIVER OF TAA-INDUCED LIVER INJURY. HUMAN CIRRHOTIC LIVERS WERE DEMONSTRATED A PARALLEL INCREASE IN THE PROTEIN LEVELS OF BRD4 AND NFKB P65 IN HSCS. THIS STUDY REVEALED THAT BRD4 WAS A KEY MOLECULAR DRIVER OF TGFBETA1-INDUCED HSC ACTIVATION AND LIVER FIBROSIS. 2023 9 3155 20 GLUTAMINE METABOLISM IN ADIPOCYTES: A BONA FIDE EPIGENETIC MODULATOR OF INFLAMMATION. A CHRONIC LOW-GRADE INFLAMMATION OF WHITE ADIPOSE TISSUE (WAT) IS ONE OF THE HALLMARKS OF OBESITY AND IS PROPOSED TO CONTRIBUTE TO INSULIN RESISTANCE AND TYPE 2 DIABETES. DESPITE THIS, THE CAUSAL MECHANISMS UNDERLYING WAT INFLAMMATION REMAIN UNCLEAR. BASED ON METABOLOMIC ANALYSES OF HUMAN WAT, PETRUS ET AL. SHOWED THAT THE AMINO ACID GLUTAMINE WAS THE MOST MARKEDLY REDUCED POLAR METABOLITE IN THE OBESE STATE. REDUCED GLUTAMINE LEVELS IN ADIPOCYTES INDUCE AN INCREASE OF URIDINE DIPHOSPHATE N-ACETYLGLUCOSAMINE (UDP-GLCNAC) LEVELS VIA INDUCTION OF GLYCOLYSIS AND THE HEXOSAMINE BIOSYNTHETIC PATHWAYS. THIS PROMOTES NUCLEAR O-GLCNACYLATION, A POSTTRANSLATIONAL MODIFICATION THAT ACTIVATES THE TRANSCRIPTION OF PRO-INFLAMMATORY GENES. CONVERSELY, GLUTAMINE SUPPLEMENTATION IN VITRO AND IN VIVO, REVERSED THESE EFFECTS. ALTOGETHER, DYSREGULATION OF INTRACELLULAR GLUTAMINE METABOLISM IN WAT ESTABLISHES AN EPIGENETIC LINK BETWEEN ADIPOCYTES AND INFLAMMATION. THIS COMMENTARY DISCUSSES THESE FINDINGS AND THEIR POSSIBLY THERAPEUTIC RELEVANCE IN RELATION TO INSULIN RESISTANCE AND TYPE 2 DIABETES. 2020 10 5995 17 TGFBETA-INDUCED FIBROBLAST ACTIVATION REQUIRES PERSISTENT AND TARGETED HDAC-MEDIATED GENE REPRESSION. TISSUE FIBROSIS IS A CHRONIC DISEASE DRIVEN BY PERSISTENT FIBROBLAST ACTIVATION THAT HAS RECENTLY BEEN LINKED TO EPIGENETIC MODIFICATIONS. HERE, WE SCREENED A SMALL LIBRARY OF EPIGENETIC SMALL-MOLECULE MODULATORS TO IDENTIFY COMPOUNDS CAPABLE OF INHIBITING OR REVERSING TGFBETA-MEDIATED FIBROBLAST ACTIVATION. WE IDENTIFIED PRACINOSTAT, AN HDAC INHIBITOR, AS A POTENT ATTENUATOR OF LUNG FIBROBLAST ACTIVATION AND CONFIRMED ITS EFFICACY IN PATIENT-DERIVED FIBROBLASTS ISOLATED FROM FIBROTIC LUNG TISSUE. MECHANISTICALLY, WE FOUND THAT HDAC-DEPENDENT TRANSCRIPTIONAL REPRESSION WAS AN EARLY AND ESSENTIAL EVENT IN TGFBETA-MEDIATED FIBROBLAST ACTIVATION. TREATMENT OF LUNG FIBROBLASTS WITH PRACINOSTAT BROADLY ATTENUATED TGFBETA-MEDIATED EPIGENETIC REPRESSION AND PROMOTED FIBROBLAST QUIESCENCE. WE CONFIRMED A SPECIFIC ROLE FOR HDAC-DEPENDENT HISTONE DEACETYLATION IN THE PROMOTER REGION OF THE ANTI-FIBROTIC GENE PPARGC1A (PGC1ALPHA) IN RESPONSE TO TGFBETA STIMULATION. FINALLY, WE IDENTIFIED HDAC7 AS A KEY FACTOR WHOSE SIRNA-MEDIATED KNOCKDOWN ATTENUATES FIBROBLAST ACTIVATION WITHOUT ALTERING GLOBAL HISTONE ACETYLATION. TOGETHER, THESE RESULTS PROVIDE NOVEL MECHANISTIC INSIGHT INTO THE ESSENTIAL ROLE HDACS PLAY IN TGFBETA-MEDIATED FIBROBLAST ACTIVATION VIA TARGETED GENE REPRESSION. 2019 11 5803 26 STING SIGNALING ACTIVATION INHIBITS HBV REPLICATION AND ATTENUATES THE SEVERITY OF LIVER INJURY AND HBV-INDUCED FIBROSIS. THE COVALENTLY CLOSED CIRCULAR DNA (CCCDNA) OF HBV PLAYS A CRUCIAL ROLE IN VIRAL PERSISTENCE AND IS ALSO A RISK FACTOR FOR DEVELOPING HBV-INDUCED DISEASES, INCLUDING LIVER FIBROSIS. STIMULATOR OF INTERFERON GENES (STING), A MASTER REGULATOR OF DNA-MEDIATED INNATE IMMUNE ACTIVATION, IS A POTENTIAL THERAPEUTIC TARGET FOR VIRAL INFECTION AND VIRUS-RELATED DISEASES. IN THIS STUDY, AGONIST-INDUCED STING SIGNALING ACTIVATION IN MACROPHAGES WAS REVEALED TO INHIBIT CCCDNA-MEDIATED TRANSCRIPTION AND HBV REPLICATION VIA EPIGENETIC MODIFICATION IN HEPATOCYTES. NOTABLY, STING ACTIVATION COULD EFFICIENTLY ATTENUATE THE SEVERITY OF LIVER INJURY AND FIBROSIS IN A CHRONIC RECOMBINANT CCCDNA (RCCCDNA) MOUSE MODEL, WHICH IS A PROVEN SUITABLE RESEARCH PLATFORM FOR HBV-INDUCED FIBROSIS. MECHANISTICALLY, STING-ACTIVATED AUTOPHAGIC FLUX COULD SUPPRESS MACROPHAGE INFLAMMASOME ACTIVATION, LEADING TO THE AMELIORATION OF LIVER INJURY AND HBV-INDUCED FIBROSIS. OVERALL, THE ACTIVATION OF STING SIGNALING COULD INHIBIT HBV REPLICATION THROUGH EPIGENETIC SUPPRESSION OF CCCDNA AND ALLEVIATE HBV-INDUCED LIVER FIBROSIS THROUGH THE SUPPRESSION OF MACROPHAGE INFLAMMASOME ACTIVATION BY ACTIVATING AUTOPHAGIC FLUX IN A CHRONIC HBV MOUSE MODEL. THIS STUDY SUGGESTS THAT TARGETING THE STING SIGNALING PATHWAY MAY BE AN IMPORTANT THERAPEUTIC STRATEGY TO PROTECT AGAINST PERSISTENT HBV REPLICATION AND HBV-INDUCED FIBROSIS. 2022 12 5973 19 TET-CATALYZED 5-HYDROXYMETHYLATION PRECEDES HNF4A PROMOTER CHOICE DURING DIFFERENTIATION OF BIPOTENT LIVER PROGENITORS. UNDERSTANDING THE PROCESSES THAT GOVERN LIVER PROGENITOR CELL DIFFERENTIATION HAS IMPORTANT IMPLICATIONS FOR THE DESIGN OF STRATEGIES TARGETING CHRONIC LIVER DISEASES, WHEREBY REGENERATION OF LIVER TISSUE IS CRITICAL. ALTHOUGH DNA METHYLATION (5MC) AND HYDROXYMETHYLATION (5HMC) ARE HIGHLY DYNAMIC DURING EARLY EMBRYONIC DEVELOPMENT, LESS IS KNOWN ABOUT THEIR ROLES AT LATER STAGES OF DIFFERENTIATION. USING AN IN VITRO MODEL OF HEPATOCYTE DIFFERENTIATION, WE SHOW HERE THAT 5HMC PRECEDES THE EXPRESSION OF PROMOTER 1 (P1)-DEPENDENT ISOFORMS OF HNF4A, A MASTER TRANSCRIPTION FACTOR OF HEPATOCYTE IDENTITY. 5HMC AND HNF4A EXPRESSION FROM P1 ARE DEPENDENT ON TEN-ELEVEN TRANSLOCATION (TET) DIOXYGENASES. IN TURN, THE LIVER PIONEER FACTOR FOXA2 IS NECESSARY FOR TET1 BINDING TO THE P1 LOCUS. BOTH FOXA2 AND TETS ARE REQUIRED FOR THE 5HMC-RELATED SWITCH IN HNF4A EXPRESSION. THE EPIGENETIC EVENT IDENTIFIED HERE MAY BE A KEY STEP FOR THE ESTABLISHMENT OF THE HEPATOCYTE PROGRAM BY HNF4A. 2017 13 6203 19 THE INFLUENCE OF EPIGENETIC MODIFICATIONS ON METABOLIC CHANGES IN WHITE ADIPOSE TISSUE AND LIVER AND THEIR POTENTIAL IMPACT IN EXERCISE. BACKGROUND: EPIGENETIC MARKS ARE RESPONSIVE TO A WIDE VARIETY OF ENVIRONMENTAL STIMULI AND SERVE AS IMPORTANT MEDIATORS FOR GENE TRANSCRIPTION. A NUMBER OF CHROMATIN MODIFYING ENZYMES ORCHESTRATE EPIGENETIC RESPONSES TO ENVIRONMENTAL STIMULI, WITH A GROWING BODY OF RESEARCH EXAMINING HOW CHANGES IN METABOLIC SUBSTRATES OR CO-FACTORS ALTER EPIGENETIC MODIFICATIONS. SCOPE OF REVIEW: HERE, WE PROVIDE A SYSTEMATIC REVIEW OF EXISTING EVIDENCE OF METABOLISM-RELATED EPIGENETIC CHANGES IN WHITE ADIPOSE TISSUE (WAT) AND THE LIVER AND GENERATE SECONDARY HYPOTHESES ON HOW EXERCISE MAY IMPACT METABOLISM-RELATED EPIGENETIC MARKS IN THESE TISSUES. MAJOR CONCLUSIONS: EPIGENETIC CHANGES CONTRIBUTE TO THE COMPLEX TRANSCRIPTIONAL RESPONSES ASSOCIATED WITH WAT LIPOLYSIS, HEPATIC DE NOVO LIPOGENESIS, AND HEPATIC GLUCONEOGENESIS. WHILE THESE METABOLIC RESPONSES MAY HYPOTHETICALLY BE ALTERED WITH ACUTE AND CHRONIC EXERCISE, DIRECT TESTING IS NEEDED. 2021 14 3330 22 HISTONE DEACETYLASE INHIBITOR GIVINOSTAT ALLEVIATES LIVER FIBROSIS BY REGULATING HEPATIC STELLATE CELL ACTIVATION. HEPATIC FIBROSIS, A COMMON PATHOLOGICAL MANIFESTATION OF CHRONIC LIVER INJURY, IS GENERALLY CONSIDERED TO BE THE END RESULT OF AN INCREASE IN EXTRACELLULAR MATRIX PRODUCED BY ACTIVATED HEPATIC STELLATE CELLS (HSCS). THE AIM OF THE PRESENT STUDY WAS TO TARGET THE MECHANISMS UNDERLYING HSC ACTIVATION IN ORDER TO PROVIDE A POWERFUL THERAPEUTIC STRATEGY FOR THE PREVENTION AND TREATMENT OF LIVER FIBROSIS. IN THE PRESENT STUDY, A HIGH?THROUGHPUT SCREENING ASSAY WAS ESTABLISHED, AND THE HISTONE DEACETYLASE INHIBITOR GIVINOSTAT WAS IDENTIFIED AS A POTENT INHIBITOR OF HSC ACTIVATION IN VITRO. GIVINOSTAT SIGNIFICANTLY INHIBITED HSC ACTIVATION IN VIVO, AMELIORATED CARBON TETRACHLORIDE?INDUCED MOUSE LIVER FIBROSIS AND LOWERED PLASMA AMINOTRANSFERASES. TRANSCRIPTOMIC ANALYSIS REVEALED THE MOST SIGNIFICANTLY REGULATED GENES IN THE GIVINOSTAT TREATMENT GROUP IN COMPARISON WITH THOSE IN THE SOLVENT GROUP, AMONG WHICH, DERMOKINE (DMKN), MESOTHELIN (MSLN) AND UROPLAKIN?3B (UPK3B) WERE IDENTIFIED AS POTENTIAL REGULATORS OF HSC ACTIVATION. GIVINOSTAT SIGNIFICANTLY REDUCED THE MRNA EXPRESSION OF DMKN, MSLN AND UPK3B IN BOTH A MOUSE LIVER FIBROSIS MODEL AND IN HSC?LX2 CELLS. KNOCKDOWN OF ANY OF THE AFOREMENTIONED GENES INHIBITED THE TGF?BETA1?INDUCED EXPRESSION OF ALPHA?SMOOTH MUSCLE ACTIN AND COLLAGEN TYPE I, INDICATING THAT THEY ARE CRUCIAL FOR HSC ACTIVATION. IN SUMMARY, USING A NOVEL STRATEGY TARGETING HSC ACTIVATION, THE PRESENT STUDY IDENTIFIED A POTENTIAL EPIGENETIC DRUG FOR THE TREATMENT OF HEPATIC FIBROSIS AND REVEALED NOVEL REGULATORS OF HSC ACTIVATION. 2021 15 3242 25 HEPATIC NCOR1 DELETION EXACERBATES ALCOHOL-INDUCED LIVER INJURY IN MICE BY PROMOTING CCL2-MEDIATED MONOCYTE-DERIVED MACROPHAGE INFILTRATION. NUCLEAR RECEPTOR COREPRESSOR 1 (NCOR1) IS A COREPRESSOR OF THE EPIGENETIC REGULATION OF GENE TRANSCRIPTION THAT HAS IMPORTANT FUNCTIONS IN METABOLISM AND INFLAMMATION, BUT LITTLE IS KNOWN ABOUT ITS ROLE IN ALCOHOL-ASSOCIATED LIVER DISEASE (ALD). IN THIS STUDY, WE DEVELOPED MICE WITH HEPATOCYTE-SPECIFIC NCOR1 KNOCKOUT (NCOR1(HEP-/-)) USING THE ALBUMIN-CRE/LOXP SYSTEM AND INVESTIGATED THE ROLE OF NCOR1 IN THE PATHOGENESIS OF ALD AND THE UNDERLYING MECHANISMS. THE TRADITIONAL ALCOHOL FEEDING MODEL AND NIAAA MODEL OF ALD WERE BOTH ESTABLISHED IN WILD-TYPE AND NCOR1(HEP-/-) MICE. WE SHOWED THAT AFTER ALD WAS ESTABLISHED, NCOR1(HEP-/-) MICE HAD WORSE LIVER INJURY BUT LESS STEATOSIS THAN WILD-TYPE MICE. WE DEMONSTRATED THAT HEPATOCYTE-SPECIFIC LOSS OF NCOR1 ATTENUATED LIVER STEATOSIS BY PROMOTING FATTY ACID OXIDATION BY UPREGULATING BMAL1 (A CIRCADIAN CLOCK COMPONENT THAT HAS BEEN REPORTED TO PROMOTE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA (PPARALPHA)-MEDIATED FATTY BETA-OXIDATION BY UPREGULATING DE NOVO LIPID SYNTHESIS). ON THE OTHER HAND, HEPATOCYTE-SPECIFIC LOSS OF NCOR1 EXACERBATED ALCOHOL-INDUCED LIVER INFLAMMATION AND OXIDATIVE STRESS BY RECRUITING MONOCYTE-DERIVED MACROPHAGES VIA C-C MOTIF CHEMOKINE LIGAND 2 (CCL2). IN THE MOUSE HEPATOCYTE LINE AML12, NCOR1 KNOCKDOWN SIGNIFICANTLY INCREASED ETHANOL-INDUCED CCL2 RELEASE. THESE RESULTS SUGGEST THAT HEPATOCYTE NCOR1 PLAYS DISTINCT ROLES IN CONTROLLING LIVER INFLAMMATION AND STEATOSIS, WHICH PROVIDES NEW INSIGHTS INTO THE DEVELOPMENT OF TREATMENTS FOR STEATOHEPATITIS INDUCED BY CHRONIC ALCOHOL CONSUMPTION. 2022 16 469 22 ARID1A LOSS DRIVES NONALCOHOLIC STEATOHEPATITIS IN MICE THROUGH EPIGENETIC DYSREGULATION OF HEPATIC LIPOGENESIS AND FATTY ACID OXIDATION. NONALCOHOLIC STEATOHEPATITIS (NASH) IS A RAPIDLY GROWING CAUSE OF CHRONIC LIVER DAMAGE, CIRRHOSIS, AND HEPATOCELLULAR CARCINOMA. HOW FATTY LIVER PATHOGENESIS IS SUBJECT TO EPIGENETIC REGULATION IS UNKNOWN. WE HYPOTHESIZED THAT CHROMATIN REMODELING IS IMPORTANT FOR THE PATHOGENESIS OF FATTY LIVER DISEASE. AT-RICH INTERACTIVE DOMAIN-CONTAINING PROTEIN 1A (ARID1A), A DNA-BINDING COMPONENT OF THE SWITCH/SUCROSE NONFERMENTABLE ADENOSINE TRIPHOSPHATE-DEPENDENT CHROMATIN-REMODELING COMPLEX, CONTRIBUTES TO NUCLEOSOME REPOSITIONING AND ACCESS BY TRANSCRIPTIONAL REGULATORS. LIVER-SPECIFIC DELETION OF ARID1A (ARID1A LIVER KNOCKOUT [LKO]) CAUSED THE DEVELOPMENT OF AGE-DEPENDENT FATTY LIVER DISEASE IN MICE. TRANSCRIPTOME ANALYSIS REVEALED UP-REGULATION OF LIPOGENESIS AND DOWN-REGULATION OF FATTY ACID OXIDATION GENES. AS EVIDENCE OF DIRECT REGULATION, ARID1A DEMONSTRATED DIRECT BINDING TO THE PROMOTERS OF MANY OF THESE DIFFERENTIALLY REGULATED GENES. ADDITIONALLY, ARID1A LKO MICE WERE MORE SUSCEPTIBLE TO HIGH-FAT DIET-INDUCED LIVER STEATOSIS AND FIBROSIS. WE DELETED PTEN IN COMBINATION WITH ARID1A TO SYNERGISTICALLY DRIVE FATTY LIVER PROGRESSION. INHIBITION OF LIPOGENESIS USING CAT-2003, A POTENT STEROL REGULATORY ELEMENT-BINDING PROTEIN INHIBITOR, MEDIATED IMPROVEMENTS IN MARKERS OF FATTY LIVER DISEASE PROGRESSION IN THIS ARID1A/PTEN DOUBLE KNOCKOUT MODEL. CONCLUSION: ARID1A PLAYS A ROLE IN THE EPIGENETIC REGULATION OF HEPATIC LIPID HOMEOSTASIS, AND ITS SUPPRESSION CONTRIBUTES TO FATTY LIVER PATHOGENESIS. COMBINED ARID1A AND PTEN DELETION SHOWS ACCELERATED FATTY LIVER DISEASE PROGRESSION AND IS A USEFUL MOUSE MODEL FOR STUDYING THERAPEUTIC STRATEGIES FOR NASH. 2019 17 1764 28 EARLY-IMMEDIATE GENE EGR1 IS ASSOCIATED WITH TGFBETA1 REGULATION OF EPIGENETIC READER BROMODOMAIN-CONTAINING PROTEIN 4 VIA THE CANONICAL SMAD3 SIGNALING IN HEPATIC STELLATE CELLS IN VITRO AND IN VIVO. UPON CHRONIC DAMAGE TO THE LIVER, MULTIPLE CYTOKINES STIMULATE HEPATIC STELLATE CELLS (HSCS), CAUSING THE ALTERATIONS OF GENE EXPRESSION PROFILES AND THUS LEADING TO HSC ACTIVATION, A KEY STEP IN LIVER FIBROGENESIS. ACTIVATED HSCS ARE THE DOMINANT CONTRIBUTORS TO LIVER FIBROSIS. BROMODOMAIN CONTAINING PROTEIN 4 (BRD4), AN IMPORTANT EPIGENETIC READER, WAS DEMONSTRATED TO CONCENTRATE ON HUNDREDS OF ENHANCERS ASSOCIATED WITH GENES INVOLVED IN MULTIPLE PROFIBROTIC PATHWAYS, THEREBY DIRECTING HSC ACTIVATION AND THE FIBROTIC RESPONSES. THE PRESENT STUDIES WERE DESIGNED TO EXAMINE THE EFFECT OF TRANSFORMING GROWTH FACTOR BETA-1 (TGFBETA1), THE MOST POTENT PRO-FIBROTIC CYTOKINE, ON BRD4 EXPRESSION IN HSCS AND, IF SO, ELUCIDATED THE UNDERLYING MECHANISMS IN VITRO AND IN VIVO. THE EXPERIMENTS EMPLOYED THE HETEROGENEOUS TGFBETA1 KNOCKOUT (TGFBETA1(+/-) ) MICE, GENE KNOCKDOWN IN VIVO, AND A MODEL OF THIOACETAMIDE (TAA)-INDUCED LIVER INJURY. THE RESULTS REVEALED THAT TGFBETA1 ENHANCED BRD4 EXPRESSION IN HSCS, WHICH WAS MEDIATED, AT LEAST, BY SMAD3 SIGNALING AND EARLY-IMMEDIATE GENE EGR1 (EARLY GROWTH RESPONSE-1). TGFBETA1-INDUCED SMAD3 SIGNALING INCREASED EGR1 EXPRESSION AND PROMOTED EGR1 BINDING TO BRD4 PROMOTER AT A SITE AROUND -111 BP, PROMOTING BRD4 EXPRESSION. EGR1 KNOCKDOWN REDUCED BRD4 EXPRESSION IN HSCS IN A MOUSE MODEL OF TAA-INDUCED LIVER INJURY AND LESSENED LIVER FIBROSIS. DOUBLE FLUORESCENCE STAINING DEMONSTRATED A STRONG INCREASE IN BRD4 EXPRESSION IN ACTIVATED HSCS IN FIBROTIC AREAS OF THE HUMAN LIVERS, PARALLELING THE UPREGULATION OF P-SMAD3 AND EGR1. THIS RESEARCH SUGGESTED NOVEL MOLECULAR EVENTS UNDERLYING THE ROLES OF THE MASTER PRO-FIBROTIC CYTOKINE TGFBETA1 IN HSC ACTIVATION AND LIVER FIBROGENESIS. 2022 18 5715 25 SIRT3 RESTRICTS HEPATITIS B VIRUS TRANSCRIPTION AND REPLICATION THROUGH EPIGENETIC REGULATION OF COVALENTLY CLOSED CIRCULAR DNA INVOLVING SUPPRESSOR OF VARIEGATION 3-9 HOMOLOG 1 AND SET DOMAIN CONTAINING 1A HISTONE METHYLTRANSFERASES. HEPATITIS B VIRUS (HBV) INFECTION REMAINS A MAJOR HEALTH PROBLEM WORLDWIDE. MAINTENANCE OF THE COVALENTLY CLOSED CIRCULAR DNA (CCCDNA), WHICH SERVES AS A TEMPLATE FOR HBV RNA TRANSCRIPTION, IS RESPONSIBLE FOR THE FAILURE OF ERADICATING CHRONIC HBV DURING CURRENT ANTIVIRAL THERAPY. CCCDNA IS ASSEMBLED WITH CELLULAR HISTONE PROTEINS INTO CHROMATIN, BUT LITTLE IS KNOWN ABOUT THE REGULATION OF HBV CHROMATIN BY HISTONE POSTTRANSLATIONAL MODIFICATIONS. IN THIS STUDY, WE IDENTIFIED SILENT MATING TYPE INFORMATION REGULATION 2 HOMOLOG 3 (SIRT3) AS A HOST FACTOR RESTRICTING HBV TRANSCRIPTION AND REPLICATION BY SCREENING SEVEN MEMBERS OF THE SIRTUIN FAMILY, WHICH IS THE CLASS III HISTONE DEACETYLASE. ECTOPIC SIRT3 EXPRESSION SIGNIFICANTLY REDUCED TOTAL HBV RNAS, 3.5-KB RNA, AS WELL AS REPLICATIVE INTERMEDIATE DNA IN HBV-INFECTED HEPG2-NA(+) /TAUROCHOLATE COTRANSPORTING POLYPEPTIDE CELLS AND PRIMARY HUMAN HEPATOCYTES. IN CONTRAST, GENE SILENCING OF SIRT3 PROMOTED HBV TRANSCRIPTION AND REPLICATION. A MECHANISTIC STUDY FOUND THAT NUCLEAR SIRT3 WAS RECRUITED TO THE HBV CCCDNA, WHERE IT DEACETYLATED HISTONE 3 LYSINE 9. IMPORTANTLY, OCCUPANCY OF SIRT3 ON CCCDNA COULD INCREASE THE RECRUITMENT OF HISTONE METHYLTRANSFERASE SUPPRESSOR OF VARIEGATION 3-9 HOMOLOG 1 TO CCCDNA AND DECREASE RECRUITMENT OF SET DOMAIN CONTAINING 1A, LEADING TO A MARKED INCREASE OF TRIMETHYL-HISTONE H3 (LYS9) AND A DECREASE OF TRIMETHYL-HISTONE H3 (LYS4) ON CCCDNA. MOREOVER, SIRT3-MEDIATED HBV CCCDNA TRANSCRIPTIONAL REPRESSION INVOLVED DECREASED BINDING OF HOST RNA POLYMERASE II AND TRANSCRIPTION FACTOR YIN YANG 1 TO CCCDNA. FINALLY, HEPATITIS B VIRAL X PROTEIN COULD RELIEVE SIRT3-MEDIATED CCCDNA TRANSCRIPTIONAL REPRESSION BY INHIBITING BOTH SIRT3 EXPRESSION AND ITS RECRUITMENT TO CCCDNA. CONCLUSION: SIRT3 IS A HOST FACTOR EPIGENETICALLY RESTRICTING HBV CCCDNA TRANSCRIPTION BY ACTING COOPERATIVELY WITH HISTONE METHYLTRANSFERASE; THESE DATA PROVIDE A RATIONALE FOR THE USE OF SIRT3 ACTIVATORS IN THE PREVENTION OR TREATMENT OF HBV INFECTION. (HEPATOLOGY 2018). 2018 19 4020 26 LOW-MOLECULAR-WEIGHT FIBROBLAST GROWTH FACTOR 2 ATTENUATES HEPATIC FIBROSIS BY EPIGENETIC DOWN-REGULATION OF DELTA-LIKE1. LIVER FIBROSIS, A MAJOR CAUSE OF END-STAGE LIVER DISEASES, IS CLOSELY REGULATED BY MULTIPLE GROWTH FACTORS AND CYTOKINES. THE CORRELATION OF FIBROBLAST GROWTH FACTOR 2 (FGF2) WITH CHRONIC LIVER INJURY HAS BEEN REPORTED, BUT THE EXACT FUNCTIONS OF DIFFERENT FGF2 ISOFORMS IN LIVER FIBROGENESIS REMAIN UNCLEAR. HERE, WE REPORT ON THE DIFFERENTIAL EXPRESSION PATTERNS AND FUNCTIONS OF LOW- AND HIGH-MOLECULAR-WEIGHT FGF2 (NAMELY, FGF2(LMW) AND FGF2(HMW) , RESPECTIVELY) IN HEPATIC FIBROGENESIS USING A CCL4 -INDUCED MOUSE LIVER FIBROSIS MODEL. FGF2(HMW) DISPLAYED A ROBUST INCREASE IN CCL4 -INDUCED HEPATIC FIBROSIS AND PROMOTED FIBROGENESIS. IN CONTRAST, ENDOGENOUS FGF2(LMW) EXHIBITED A SLIGHT INCREASE IN HEPATIC FIBROSIS AND SUPPRESSED THIS PATHOLOGICAL PROGRESSION. MOREOVER, EXOGENOUS ADMINISTRATION OF RECOMBINANT FGF2(LMW) POTENTLY AMELIORATED CCL4 -INDUCED LIVER FIBROSIS. MECHANISTICALLY, WE SHOWED THAT FGF2(LMW) TREATMENT ATTENUATED HEPATIC STELLATE CELL ACTIVATION AND FIBROSIS BY EPIGENETIC DOWN-REGULATION OF DELTA-LIKE 1 EXPRESSION THROUGH THE P38 MITOGEN-ACTIVATED PROTEIN KINASE PATHWAY. CONCLUSION: FGF2(LMW) AND FGF2(HMW) HAVE DISTINCT ROLES IN LIVER FIBROGENESIS. THESE FINDINGS DEMONSTRATE A POTENT ANTIFIBROTIC EFFECT OF FGF2(LMW) ADMINISTRATION, WHICH MAY PROVIDE A NOVEL APPROACH TO TREAT CHRONIC LIVER DISEASES. 2015 20 2964 18 GENETIC AND EPIGENETIC MECHANISMS UNDERLYING ARSENIC-ASSOCIATED DIABETES MELLITUS: A PERSPECTIVE OF THE CURRENT EVIDENCE. CHRONIC EXPOSURE TO ARSENIC HAS BEEN ASSOCIATED WITH THE DEVELOPMENT OF DIABETES MELLITUS (DM), A DISEASE CHARACTERIZED BY HYPERGLYCEMIA RESULTING FROM DYSREGULATION OF GLUCOSE HOMEOSTASIS. THIS REVIEW SUMMARIZES FOUR MAJOR MECHANISMS BY WHICH ARSENIC INDUCES DIABETES, NAMELY INHIBITION OF INSULIN-DEPENDENT GLUCOSE UPTAKE, PANCREATIC BETA-CELL DAMAGE, PANCREATIC BETA-CELL DYSFUNCTION AND STIMULATION OF LIVER GLUCONEOGENESIS THAT ARE SUPPORTED BY BOTH IN VIVO AND IN VITRO STUDIES. ADDITIONALLY, THE ROLE OF POLYMORPHIC VARIANTS ASSOCIATED WITH ARSENIC TOXICITY AND DISEASE SUSCEPTIBILITY, AS WELL AS EPIGENETIC MODIFICATIONS ASSOCIATED WITH ARSENIC EXPOSURE, ARE CONSIDERED IN THE CONTEXT OF ARSENIC-ASSOCIATED DM. TAKEN TOGETHER, IN VITRO, IN VIVO AND HUMAN GENETIC/EPIGENETIC STUDIES SUPPORT THAT ARSENIC HAS THE POTENTIAL TO INDUCE DM PHENOTYPES AND IMPAIR KEY PATHWAYS INVOLVED IN THE REGULATION OF GLUCOSE HOMEOSTASIS. 2017